Composecure, Inc. 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common stock, par value $0.0001 per share CMPO NYSE Indicate by c

Filing Documents

• tm2534272d1_8k.htm (8-K) — 32KB
• 0001104659-25-124322.txt ( ) — 195KB
• cmpo-20251223.xsd (EX-101.SCH) — 3KB
• cmpo-20251223_lab.xml (EX-101.LAB) — 33KB
• cmpo-20251223_pre.xml (EX-101.PRE) — 22KB
• tm2534272d1_8k_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. As previously disclosed, on November 2, 2025, CompoSecure, Inc., a Delaware corporation (the "Company"), and certain of its subsidiaries entered into a Share Purchase Agreement (as it may be amended from time to time, the "Transaction Agreement") with Husky Technologies Limited ("Husky"), Platinum Equity Advisors, LLC ("Platinum"), certain entities affiliated with Platinum and certain members of Husky management. On November 2, 2025, concurrently with the execution of the Transaction Agreement, the Company also entered into purchase agreements (the "Purchase Agreements") with certain investors named therein. The Company held a Special Meeting of stockholders (the "Special Meeting") on December 23, 2025. At the Special Meeting, the proposal to approve the issuance of shares of the Company's Class A Common Stock, par value $0.0001 per share ("Common Stock"), in connection with the transactions contemplated by, and pursuant to the terms of, the Share Purchase Agreement and the Purchase Agreements (the "Transactions" and such proposal, the "Stock Issuance Proposal") was submitted to a vote of the Company's stockholders. The Stock Issuance Proposal is described in more detail in the Company's definitive proxy At the close of business on November 20, 2025, the record date for the determination of stockholders entitled to vote at the Special Meeting, there was an aggregate of 126,411,164 shares of the Company's Common Stock outstanding and entitled to vote at the Special Meeting. The holders of 105,808,530 shares of Common Stock, representing approximately 83.70% of the voting power of the issued and outstanding shares of Common Stock as of the record date, were represented virtually or by proxy at the Special Meeting, constituting a quorum. At the Special Meeting, the Stock Issuance Proposal was approved. The vote with

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking letters and complaints relating to the Transactions, the timing and completion of the Transactions, expected benefits, future plans, expectations and opportunities, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Important factors include, among others: (i) the risk that the Transactions may not be completed in a timely manner or at all; (ii) the failure to obtain required approvals, including regulatory approvals; (iii) the occurrence of any event that could give rise to termination of the Share Purchase Agreement; (iv) the effect of the announcement, pendency or consummation of the Transactions on the parties' business relationships, operations, financial and accounting matters; (v) risks that the expected benefits of the Transactions, including financial projections, estimates and outlook, may not be fully realized or may take longer to realize than expected; (vi) risks related to financing the Transactions; (vii) costs related to the Transactions; (viii) potential litigation and/or regulatory actions relating to the Transactions, including the demand letters and Complaints described herein, and otherwise; (ix) general economic, market, industry and competitive conditions; and (x) other risks and uncertainties described in CompoSecure's filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q, which identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking

View Full Filing

View this 8-K filing on SEC EDGAR